Anxiety Disorders - Global Strategic Business Report

Global Industry Analysts, Inc, April 2012, Pages: 615

This report analyzes the worldwide markets for Anxiety Disorders in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets.

The report profiles 63 companies including many key and niche players such as AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline Plc, H. Lundbeck A/S, Mylan, Inc., Neurocrine Biosciences, Inc., Pfizer, Inc., Ratiopharm, Sanofi, UCB SA, Valeant Pharmaceuticals International, and Watson Laboratories, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying.

ANXIETY DISORDERS

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3

II. Executive Summary

1. INDUSTRY OVERVIEW II-1
Anxiety Disorders: A Prelude II-1
Future Outlook - Market Challenged by Generics and Efficacy
Issues II-1
A Snapshot of the Global Market Opportunity II-2
Prevalence of Specific Anxiety Disorders II-2
Generalized Anxiety Disorder (GAD) II-2
Obsessive-Compulsive Disorder (OCD) II-2
Specific Phobias II-2
Social Phobias II-3
Panic Disorder II-3
Post Traumatic Stress Disorder (PTSD) II-3
Social Anxiety Disorder (SAD) II-3
Anxiety Disorders Can Strike At Any Age II-3
Shyness: A Form of Anxiety Disorder among Kids and Teenagers II-3
Table 1: Average Age of Onset for Select Anxiety Disorders
(includes corresponding Graph/Chart) II-4
Women - The Most Affected Lot with Anxiety II-4
Table 2: Female to Male Ratio for Incidence of Anxiety
Disorders by Type of Disorder (includes corresponding
Graph/Chart) II-4
Patent Expiries - A Major Impediment to Market Growth II-5
Patent Expiries of Select Leading Drugs Indicated for Anxiety
Disorders II-5
Leading Drugs and Indications for Anxiety Disorders II-5

2. PHARMACOLOGICAL TREATMENT FOR ANXIETY DISORDERS II-7
Pharmacological Treatment II-7
Available Treatment for Anxiety Disorders - In a Nutshell II-8
Antidepressants for Anxiety Disorders II-8
Selective Serotonin Reuptake Inhibitors (SSRIs) II-8
Zoloft (Sertraline) II-9
Paxil (Paroxetine) II-9
Prozac (Fluoxetine) II-9
Cipralex/Lexapro (Escitalopram) II-9
Competitive Scenario - Cymbalta Emerges as a Market Leader
in Anti-Depressants Market II-9
Table 3: Select Leading Anti-Depressants indicated for
Anxiety Disorders (2007-2009): Annual Revenues for
Cymbalta, Lexapro, Paxil & Wellbutrin, Effexor, Zoloft, and
Remeron in US$ Million (includes corresponding Graph/Chart) II-10
Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) II-11
Cymbalta (Duloxetine) II-11
Effexor (Venlafaxine) II-11
Monoamine Oxidase Inhibitors (MAOIs) II-11
Tricyclic and Tetracyclic Antidepressants (TCAs) II-11
Other Antidepressants II-12
Sedatives II-12
Benzodiazepines (BZDs) II-12
Other Medications II-12
Obsessive Compulsive Disorder (OCD) Treatment II-13
Table 4: Dosing of Select Serotonin Reuptake Inhibitors in
OCD Treatment II-13
Generalized Anxiety Disorder (GAD) Treatment II-14
Drugs Indicated for the Treatment of Generalized Anxiety
Disorder (GAD) II-14
Novel Therapies for GAD on the Anvil II-15
Novel Compounds Under Investigation for Generalized Anxiety
Disorder (GAD) II-15

3. DRUG PIPELINE ANALYSIS II-16
Select Anti-Anxiety Pipeline Drugs in Phase III Development
Stage and Filed for Approval II-16
Select Anti-Anxiety Pipeline Drugs in Phase II Development Stage II-16
Select Anti-Anxiety Pipeline Drugs in Phase I Development Stage II-17

4. NON-PHARMACOLOGICAL TREATMENT II-18
Psychological Treatment II-18
Cognitive Behavioral Therapy II-18
Relaxation Techniques II-18
Biofeedback II-18
Hypnotherapy II-18
Meditation II-18
Natural Remedies for Treating Anxiety II-19
Acupuncture II-19
Other Treatment Options II-19
Support Program II-19
Changes in Lifestyle II-19

5. ANXIETY DISORDERS - THE DISEASE, CAUSES, SYMPTOMS, AND
EVALUATION METHODS II-20
What is Anxiety Disorder? II-20
Types of Anxiety Disorders II-20
A Review of Anxiety Disorders II-20
Generalized Anxiety Disorder (GAD) II-20
Panic Disorder II-21
Phobias II-21
Agoraphobia II-22
Social Phobia II-22
Obsessive-Compulsive Disorder (OCD) II-23
Symptoms, Obsessions and Compulsions of Obsessive-Compulsive
Disorder II-24
Particular Phobic Anxiety Disorder (PPAD) II-24
Post-Traumatic Stress Disorder (PTSD) II-24
Separation Anxiety Disorder (SAD) II-25
Anxiety Disorders in Children II-25
Anxiety Disorders in Teens II-26
Causes and Factors for Anxiety Disorder II-26
Symptoms II-27
Diagnosis for Anxiety Disorders II-28

6. PRODUCT APPROVALS AND LAUNCHES II-29
Sun Pharma Receives FDA Approval to Commercialize Generic
Cymbalta II-29
Impax Receives Tentative FDA Approval for Generic Version of
Cymbalta II-29
Actavis Receives FDA Approval for Alprazolam II-29
Sun Pharma Receives FDA Approval to Generic Version of Alprazolam II-29
Bafna Pharmaceuticals Receives Approval for Anxiety Drug in UK II-29
Coenzyme-A Technologies Introduces MODULATOR MATRIX I II-30
Sun Pharma to Launch Generic Version of Venlafaxine II-30
Eli Lilly Receives FDA Approval for Cymbalta for Treating GAD II-30
Aurobindo Pharma Receives Tentative US FDA Approval for
Escitalopram II-30
Boehringer Ingelheim and Eli Lilly Obtain Approval for
Cymbalta in Canada II-31
Medtronics Reclaim Deep Brain Stimulation Therapy Receives
CE-Mark Approval II-31
Otsuka Pharmaceutical and BMS Obtain FDA Approval for sNDA II-31
Servier Obtains EMEA Approval for Valdoxan in Treating Major
Depressive Episodes II-32
Boehringer Ingelheim and Eli Lilly Receive EU Approval for
Cymbalta in GAD II-32
AstraZeneca Files for Approval of Seroquel XR for GAD in Europe II-33
Glenmark Pharmaceuticals Launches Hydroxyzine Hydrochloride
Tablets II-33
Jazz Pharma Launches Once-A-Day LUVOX® CR Extended-Release
Capsules II-33

7. RECENT INDUSTRY ACTIVITY II-35
Euthymics Acquires DOV Pharma II-35
Abbott Acquires Solvay Pharmaceuticals II-35
Pfizer Withdraws sNDA for Lyrica in Treating GAD II-35
Eli Lilly Drags Sun Pharma to Court for Alleged Infringment of
Cymbalta Patent II-36
Pfizer Discontinues Late Stage Development of GAD Drug Candidate II-36
Pacgen Biopharmaceuticals Acquires Xphase Pharmaceuticals II-36
GSK Inks Agreement for Divesting Wellbutrin XL® Rights to
Biovail International II-37
Ligand Pharmaceuticals Acquires Neurogen II-37
FDA Seeks Additional Information for Seroquel XR sNDA in GAD
Treatment II-37
AstraZeneca's Seroquel XR™ Shows Improvement in GAD Symptoms II-37
Synosia Therapeutics Begins Phase II Efficacy Trial for
Rufinamide II-38
Ambien CR® Improves Chronic Insomnia in Patients with Co-
morbid GAD II-38
AstraZeneca Files sNDA for Seroquel XR for Treating GAD II-38
Bionomics Concludes GMP Synthesis of BNC210 II-39
OJSC Pharmstandard to Take Over Afobazol® Trademark II-39

8. FOCUS ON SELECT GLOBAL PLAYERS II-40
AstraZeneca Plc. (UK) II-40
Boehringer Ingelheim GmbH (Germany) II-40
Bristol-Myers Squibb Company (US) II-40
Eli Lilly and Company (US) II-41
F. Hoffmann-La Roche Ltd. (Switzerland) II-41
Forest Laboratories, Inc. (US) II-42
GlaxoSmithKline Plc. (UK) II-42
H. Lundbeck A/S (Denmark) II-43
Mylan, Inc. (US) II-43
Neurocrine Biosciences, Inc. (US) II-43
Pfizer, Inc. (US) II-44
Ratiopharm (Germany) II-44
Sanofi (France) II-44
UCB SA (Belgium) II-45
Valeant Pharmaceuticals International (US) II-45
Watson Laboratories, Inc. (US) II-45

9. GLOBAL MARKET PERSPECTIVE II-46
Table 5: World Recent Past, Current and Future Analysis for
Anxiety Disorders by Geographic Region - US, Europe,
Asia-Pacific, and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2009
through 2017 (includes corresponding Graph/Chart) II-46

Table 6: World Historic Review for Anxiety Disorders by
Geographic Region - US, Europe, Asia-Pacific, and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-47

Table 7: World 15-Year Perspective for Anxiety Disorders by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Europe, Asia-Pacific, and Rest of World Markets for Years
2003, 2011 & 2017 (includes corresponding Graph/Chart) II-48

III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Anxiety Disorders - A Major Health Burden III-1
Prevalence of Anxiety Disorders III-1
Table 8: US Prevalence of Anxiety Disorders by Type
(includes corresponding Graph/Chart) III-1
Product Approvals and Launches III-2
Strategic Corporate Developments III-5
Select Players III-7
Bristol-Myers Squibb Company III-7
Eli Lilly and Company III-8
Forest Laboratories, Inc. III-8
Mylan, Inc. III-9
Neurocrine Biosciences, Inc. III-9
Pfizer, Inc. III-9
Valeant Pharmaceuticals International III-9
Watson Laboratories, Inc. III-10
B.Market Analytics III-10
Table 9: The US Recent Past, Current & Future Analysis for
Anxiety Disorders Market With Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-10

Table 10: The US Historic Review for Anxiety Disorders
Market With Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-11

2. EUROPE III-12
A.Market Analysis III-12
Product Approval III-12
B.Market Analytics III-13
Table 11: European Recent Past, Current & Future Analysis
for Anxiety Disorders by Geographic Region - France,
Germany, Italy, UK, Spain, and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-13

Table 12: European Historic Review for Anxiety Disorders
Market by Geographic Region - France, Germany, Italy, UK,
Spain, and Rest of Europe Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-14

Table 13: European 15-Year Perspective for Anxiety Disorders
by Geographic Region - Percentage Breakdown of Dollar Sales
for France, Germany, Italy, UK, Spain, and Rest of Europe
Markets for Years 2003, 2011 & 2017 (includes corresponding
Graph/Chart) III-15

2a. FRANCE III-16
A.Market Analysis III-16
Clinical Trials/Product Approvals III-16
Select Player III-16
B.Market Analytics III-17
Table 14: French Recent Past, Current & Future Analysis for
Anxiety Disorders Market with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-17

Table 15: French Historic Review for Anxiety Disorders
Market with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-18

2b. GERMANY III-19
A.Market Analysis III-19
Product Approval III-19
Select Players III-19
B.Market Analytics III-20
Table 16: German Recent Past, Current & Future Analysis for
Anxiety Disorders Market with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-20

Table 17: German Historic Review for Anxiety Disorders
Market with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-21

2c. ITALY III-22
A.Market Analysis III-22
Select Player III-22
Polifarma SpA III-22
B.Market Analytics III-22
Table 18: Italian Recent Past, Current & Future Analysis for
Anxiety Disorders Market with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-22

Table 19: Italian Historic Review for Anxiety Disorders
Market with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-23

2d. THE UNITED KINGDOM III-24
A.Market Analysis III-24
An Overview of the Market Opportunity III-24
Table 20: Prevalence of Depression and Anxiety Disorders in
the UK (2006): Percentage of Adult Population (16-75 Years)
Affection by Condition (includes corresponding Graph/Chart) III-24
Product Approvals/Clinical Trials III-25
Select Players III-26
B.Market Analytics III-27
Table 21: The UK Recent Past, Current & Future Analysis for
Anxiety Disorders Market with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-27

Table 22: The UK Historic Review for Anxiety Disorders
Market with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-28

2e. SPAIN III-29
Market Analytics III-29
Table 23: Spanish Recent Past, Current & Future Analysis for
Anxiety Disorders Market with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-29

Table 24: Spanish Historic Review for Anxiety Disorders
Market with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-30

2f. REST OF EUROPE III-31
A.Market Analysis III-31
Strategic Corporate Development III-31
Select Players III-31
B.Market Analytics III-33
Table 25: Rest of European Recent Past, Current & Future
Analysis for Anxiety Disorders Market with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-33

Table 26: Rest of European Historic Review for Anxiety
Disorders Market with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-34

3. ASIA-PACIFIC III-35
A.Market Analysis III-35
Anxiety and Depression - A Major Debilitating Condition in
Australia III-35
Table 27: 12-Month Prevalence of Anxiety Disorders in
Australia by Age Group (2006) (includes corresponding
Graph/Chart) III-35
Strategic Corporate Development III-36
Select Player III-36
B.Market Analytics III-37
Table 28: Asia-Pacific Recent Past, Current & Future
Analysis for Anxiety Disorders Market with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-37

Table 29: Asia-Pacific Historic Review for Anxiety Disorders
Market with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-38

4. REST OF WORLD III-39
A.Market Analysis III-39
Product Approval III-39
Select Player III-39
Ranbaxy Egypt Ltd. (Egypt) III-39
B.Market Analytics III-40
Table 30: Rest of World Recent Past, Current & Future
Analysis for Anxiety Disorders Market with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-40

Table 31: Rest of World Historic Review for Anxiety
Disorders Market with Annual Sales Figures in US$ Million
for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-41

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 63 (including Divisions/Subsidiaries - 85)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 40
Canada 6
Japan 4
Europe 24
France 2
Germany 5
The United Kingdom 6
Italy 3
Rest of Europe 8
Asia-Pacific (Excluding Japan) 9
Africa 1
Middle East 1
------------------------------------------

Anxiety disorder is the most commonly occurring mental health condition, affecting individuals of all age groups. The disorder involves unwarranted amount of fear, anxiety, nervousness, dread or worry that renders an affected person tense and distracted. In the recent years, the number of people suffering from anxiety disorders increased considerably owing to the global financial crisis that resulted in rising unemployment rates and increasing stress levels. Ever-increasing aging global population is also one of the factors responsible for the rapid increase in sales of central nervous system drugs. Against this backdrop, there exists an ever-increasing need for developing medications that offer a faster onset of action as compared to the presently available drugs. Subsequently, the anxiety disorders market is expected to witness a transformation, with anti-psychotic drugs expected to change the future landscape of the anxiety disorder drugs market. Seroquel XR is expected to leverage first to market status, subsequent to its approval for use in generalized anxiety disorder. Manufacturers of anti-depressants are expected to enhance their products' target patient potential, considering the higher co-morbidity between depression and anxiety. However, pharmaceutical companies in the anxiety disorder drugs market are expected to be challenged by the need of maintaining and growing the market share due to the patent expiries of the three major drug brands, including Cymbalta, Lexapro and the extended release version of Effexor, during the period 2011-2013, thereby leading to strong competition among other classes of antidepressant drugs.

Pharmacotherapy, as well as psychotherapeutic approaches, has been established to be effective in treating Generalized Anxiety Disorder (GAD). The combination of these two approaches is expected to curtail limitations of any single approach and result in enhanced improvement in the condition. The combination is also helpful for patients not benefiting from any one of the methods. Several novel therapeutic drugs are currently under development for treating Generalized Anxiety Disorder (GAD). These include agents that act by modifying Neurokinins, Cholecystokinin, ?-aminobutyric acid or GABA, voltage sensitive Ca2+ channels, and serotonin 5-HT1A receptors. Research efforts have strongly moved towards 5-HT1A-Receptor Agonists, following the launch of Buspirone. A promising product in pipeline is Pregabalin that helps in modulating Ca2+ channel flow in hyperexcited neurons.

The US represents the largest regional market for anxiety disorder therapeutics worldwide, as stated by the new market research report on Anxiety Disorders. Anxiety disorders are the most common form of psychological disorder in the US. About 40 million people suffer from an anxiety disorder in the US. About 10 million Americans are believed to visit a psychiatrist for dealing with stress-related issues per annum. Anti-anxiety drugs, antidepressants and tranquilizers account for about 25% of the total prescriptions dispensed in the US per annum. About 27% of the European population suffers from brain disorders, with depression being the most prevalent health problem in several EU-Member States. However, Asia-Pacific is forecast to register the fastest growth during the analysis period, registering a compounded annual growth rate of more than 5.0% during 2009-2017.

Global Industry Analysts ©

- Abbott India Ltd. (India)
- Actavis Group (Switzerland)
- Apotex, Inc. (Canada)
- AstraZeneca PLC (UK)
- AstraZeneca Pharmaceuticals LP (USA)
- Aurobindo Pharma Ltd. (India)
- Avineuro Pharmaceuticals (USA)
- Azevan Pharmaceuticals, Inc. (USA)
- Bafna Pharmaceuticals Ltd. (India)
- Bionomics Ltd. (Australia)
- Boehringer Ingelheim GmbH (Germany)
- Boehringer Ingelheim Pharmaceuticals, Inc. (USA)
- BrainCells, Inc. (USA)
- Bristol-Myers Squibb Company (USA)
- CeNeRx BioPharma, Inc. (USA)
- Coenzyme-A Technologies, Inc. (USA)
- Daiichi Sankyo, Inc. (USA)
- Dr. Reddy's Laboratories Ltd. (India)
- Eli Lilly and Company (USA)
- Eli Lilly and Company (UK)
- Eli Lilly Canada, Inc. (Canada)
- Lilly Deutschland GmbH (Germany)
- Endo Pharmaceuticals Holding, Inc. (USA)
- Euthymics Bioscience, Inc. (USA)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Fabre-Kramer Pharmaceuticals, Inc. (USA)
- Forest Laboratories, Inc. (USA)
- Forest Pharmaceuticals, Inc. (USA)
- GlaxoSmithKline PLC (UK)
- GlaxoSmithKline Canada, Inc. (Canada)
- Glenmark Pharmaceuticals Ltd. (India)
- H. Lundbeck A/S (Denmark)
- Lundbeck Research USA, Inc. (USA)
- Lundbeck, Inc. (USA)
- Impax Laboratories, Inc. (USA)
- Jazz Pharmaceuticals, Inc. (USA)
- Johnson & Johnson (USA)
- Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. (USA)
- Les Laboratoires Servier (France)
- Meda Pharmaceuticals, Inc. (USA)
- MediciNova, Inc. (USA)
- Meiji Holdings Co., Ltd. (Japan)
- Merck & Co., Inc. (USA)
- Mylan, Inc. (USA)
- Neurocrine Biosciences, Inc. (USA)
- NeuroSearch A/S (Denmark)
- Novartis AG (Switzerland)
- Sandoz International GmbH (Germany)
- Sandoz GmbH (Austria)
- OJSC Pharmstandard (Russia)
- Olympian Labs, Inc. (USA)
- Ono Pharmaceutical Co., Ltd. (Japan)
- Otsuka Pharmaceutical Co., Ltd. (Japan)
- Pacgen Biopharmaceuticals Corporation (Canada)
- Paddock Laboratories, Inc. (USA)
- Par Pharmaceutical, Inc. (USA)
- Pfizer, Inc. (USA)
- Pfizer Australia Pty., Ltd. (Australia)
- Pfizer Canada, Inc. (Canada)
- Pfizer GmbH (Germany)
- Pfizer Ltd. (UK)
- Pherin Pharmaceuticals, Inc. (USA)
- Polifarma SpA (Italy)
- Ranbaxy Laboratories Ltd. (India)
- Ranbaxy Egypt Ltd. (Egypt)
- Ranbaxy Pharmaceuticals, Inc. (USA)
- Recordati SpA (Italy)
- Rexahn Pharmaceuticals, Inc. (USA)
- Sanofi (France)
- Sanofi-Aventis US LLC (USA)
- Sanofi-Aventis Canada, Inc. (Canada)
- SkyePharma PLC (UK)
- Stada Arzneimittel AG (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Sunovion Pharmaceuticals, Inc. (USA)
- Supernus Pharmaceuticals, Inc. (USA)
- Takeda Pharmaceutical Co., Ltd. (Japan)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Teva UK Ltd. (UK)
- UCB SA (Belgium)
- Valeant Pharmaceuticals International, Inc. (USA)
- Valeas SpA (Italy)
- Watson Pharmaceuticals, Inc. (USA)
- Watson Laboratories, Inc. (USA)
- Whewell Biosciences, Inc. (USA)

Customers who bought this item also bought

• Medical Nutrition - A Global Market Overview
• Diabetes Diagnostics - Global Strategic Business Report
• Disinfectants - Global Strategic Business Report
• Syringes (Disposable and Reusable) - Global Strategic Business Report
• Molecular Diagnostics - Global Strategic Business Report
• Dental Supplies - Global Strategic Business Report
• Anesthesia Disposables - Global Strategic Business Report
• Clinical Diagnostics Automation - Global Business Strategic Report
• Ostomy and Incontinence Products - Global Strategic Business Report
• World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast